Skip to main content
NVCR
NASDAQ Life Sciences

NovoCure's Optune Lua Secures Key Reimbursement in Japan for NSCLC Patients

Tom Rudovsky · Reported by dpa-AFX
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$13.34
Mkt Cap
$1.556B
52W Low
$9.82
52W High
$21.55
52W Position info
36% above low
Off High info
38% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

NVCR sits 36% above its 52-week low of $9.82.

Summary

NovoCure announced that Japan's Ministry of Health, Labour and Welfare has approved reimbursement for its Optune Lua device, specifically for adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC). This reimbursement approval is a critical step for commercialization, as it provides patients with access to the treatment through the country's National Health Insurance coverage. This development follows recent positive news for NovoCure, including the reinstatement of its U.S. subsidiary's billing privileges and FDA approval for Optune Pax in pancreatic cancer, signaling a strategic expansion of market access for its Tumor Treating Fields technology. Traders will view this as a significant positive catalyst, as it opens a new revenue stream in a major international market, directly impacting the company's growth prospects.

At the time of this announcement, NVCR was trading at $13.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.82 to $21.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.


Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $11.30 info
Change: -$2.65 (-19%) info
Market Cap: $1.321B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $11.30 info
Change: -$2.95 (-21%) info
Market Cap: $1.321B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.34
Real-time Price: $11.30 info
Change: -$4.04 (-26%) info
Market Cap: $1.321B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $11.30 info
Change: -$2.95 (-21%) info
Market Cap: $1.321B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $11.30 info
Change: -$4.76 (-30%) info
Market Cap: $1.321B info